相关实验视频
Updated: May 5, 2026

12:09
Studying Food Reward and Motivation in Humans
Published on: March 19, 2014
26.8K
聊天GPT-4o和4o1预览作为饮食支持工具在现实世界药物治疗肥胖计划:一个前性比较分析
Louis Talay1, Leif Lagesen2, Adela Yip3
1Faculty of Arts and Social Sciences, University of Sydney, Sydney, NSW 2050, Australia.
Healthcare (Basel, Switzerland)
|March 28, 2025
概括
先进的大型语言模型 (LLM) 显示出与人类营养学家在肥胖服务中的性能相当. 这些人工智能工具可以支持患者护理,并改善对减肥计划的访问.
科学领域:
- 医疗保健中的人工智能
- 肥胖医学 肥胖医学
- 数字健康数字健康
背景情况:
- 临床医生正在探索肥胖服务的大型语言模型 (LLM),平衡潜在的效率收益与对科学准确性和同情心的担忧.
- 以前的研究表明,ChatGPT-3可以模仿营养师对基本饮食问题的反应.
研究的目的:
- 为了比较两个ChatGPT-4o模型与人类饮食学家在药物数字减肥服务中回答复杂问题时的表现.
主要方法:
- 两个ChatGPT-4o模型和人类营养学家回答了来自现实世界患者互动的10个复杂问题 (5个广泛,5个狭窄).
- 答案被评估为科学正确性,可理解性,同理心/可联系性和可操作性.
主要成果:
- 无论是ChatGPT-4o模型,在10个问题中的任何一个问题上,人类饮食学家都没有统计学上的表现优于人类饮食学家 (p < 0.05).
- 所有四个标准的综合得分也显示,人工智能模型和人类营养学家之间没有统计学上显著的差异.
结论:
- 先进的LLM显示出在药物肥胖服务中作为支持工具的潜力.
- 需要在各种肥胖背景下进行进一步的研究,以确认LLM在生活方式指导方面的能力,以及对护理准入的影响.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
491
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
491
Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Drug Dosing: Obese Patients
372
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
372
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
445
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
330
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

